292 related articles for article (PubMed ID: 28796151)
1. Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
Tsume Y; Drelich AJ; Smith DE; Amidon GL
Molecules; 2017 Aug; 22(8):. PubMed ID: 28796151
[TBL] [Abstract][Full Text] [Related]
2. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.
Tsume Y; Hilfinger JM; Amidon GL
Mol Pharm; 2008; 5(5):717-27. PubMed ID: 18652477
[TBL] [Abstract][Full Text] [Related]
3. The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.
Tsume Y; Incecayir T; Song X; Hilfinger JM; Amidon GL
Eur J Pharm Biopharm; 2014 Apr; 86(3):514-23. PubMed ID: 24361461
[TBL] [Abstract][Full Text] [Related]
4. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Fang Y; Du F; Xu Y; Meng H; Huang J; Zhang X; Lu W; Liu S; Yu J
Colloids Surf B Biointerfaces; 2015 Apr; 128():357-362. PubMed ID: 25746328
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ
Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360
[TBL] [Abstract][Full Text] [Related]
7. Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism.
Landowski CP; Song X; Lorenzi PL; Hilfinger JM; Amidon GL
Pharm Res; 2005 Sep; 22(9):1510-8. PubMed ID: 16132363
[TBL] [Abstract][Full Text] [Related]
8. The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.
Tsume Y; Borras Bermejo B; Amidon GL
Pharmaceuticals (Basel); 2014 Jan; 7(2):169-91. PubMed ID: 24473270
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells.
Kakwere H; Ingham ES; Tumbale SK; Ferrara KW
Mater Sci Eng C Mater Biol Appl; 2020 Dec; 117():111251. PubMed ID: 32919625
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
Stephenson AA; Cao S; Taggart DJ; Vyavahare VP; Suo Z
Eur J Med Chem; 2021 Mar; 213():113135. PubMed ID: 33454548
[TBL] [Abstract][Full Text] [Related]
12. Potential of amino acid/dipeptide monoester prodrugs of floxuridine in facilitating enhanced delivery of active drug to interior sites of tumors: a two-tier monolayer in vitro study.
Tsume Y; Hilfinger JM; Amidon GL
Pharm Res; 2011 Oct; 28(10):2575-88. PubMed ID: 21671137
[TBL] [Abstract][Full Text] [Related]
13. Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as PepT1 targeting antitumor prodrugs.
Fang L; Wang M; Gou S; Liu X; Zhang H; Cao F
J Med Chem; 2014 Feb; 57(3):1116-20. PubMed ID: 24422538
[TBL] [Abstract][Full Text] [Related]
14. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
[TBL] [Abstract][Full Text] [Related]
15. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
Pasut G; Canal F; Dalla Via L; Arpicco S; Veronese FM; Schiavon O
J Control Release; 2008 May; 127(3):239-48. PubMed ID: 18346806
[TBL] [Abstract][Full Text] [Related]
16. A Cathepsin B-Sensitive Gemcitabine Prodrug for Enhanced Pancreatic Cancer Therapy.
Wang S; Cen D; Zhang C
J Pharm Sci; 2024 Jul; 113(7):1927-1933. PubMed ID: 38555998
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of enzyme targeted activation for amino acid/dipeptide monoester prodrugs of floxuridine; cathepsin D as a potential targeted enzyme.
Tsume Y; Amidon GL
Molecules; 2012 Mar; 17(4):3672-89. PubMed ID: 22450679
[TBL] [Abstract][Full Text] [Related]
18. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
[TBL] [Abstract][Full Text] [Related]
19. Stereocomplex Prodrugs of Oligo(lactic acid)
Tam YT; Huang C; Poellmann M; Kwon GS
ACS Nano; 2018 Jul; 12(7):7406-7414. PubMed ID: 29957934
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation.
Sun J; Yang D; Cui SH; Zhang HT; Fu Y; Wang JC; Zhang Q
Int J Pharm; 2019 Mar; 559():48-57. PubMed ID: 30677483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
